Clozapine Actavis Tafla 100 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

clozapine actavis tafla 100 mg

actavis group ptc ehf. - clozapinum inn - tafla - 100 mg

Clozapine Actavis Tafla 25 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

clozapine actavis tafla 25 mg

actavis group ptc ehf. - clozapinum inn - tafla - 25 mg

Pentasa Endaþarmsdreifa 1 g/100 ml Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa endaþarmsdreifa 1 g/100 ml

ferring lægemidler a/s - mesalazinum inn - endaþarmsdreifa - 1 g/100 ml

Pentasa Endaþarmsstíll 1 g Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa endaþarmsstíll 1 g

ferring lægemidler a/s - mesalazinum inn - endaþarmsstíll - 1 g

Pentasa Forðatafla 1 g Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa forðatafla 1 g

ferring lægemidler a/s - mesalazinum inn - forðatafla - 1 g

Pentasa Forðatafla 500 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa forðatafla 500 mg

ferring lægemidler a/s - mesalazinum inn - forðatafla - 500 mg

Pentasa Sachet Forðakyrni 1 g Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa sachet forðakyrni 1 g

ferring lægemidler a/s - mesalazinum inn - forðakyrni - 1 g

Pentasa Sachet Forðakyrni 2 g Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa sachet forðakyrni 2 g

ferring lægemidler a/s - mesalazinum inn - forðakyrni - 2 g

Pentasa Sachet Forðakyrni 4 g Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

pentasa sachet forðakyrni 4 g

ferring lægemidler a/s - mesalazinum inn - forðakyrni - 4 g

Orserdu Euroopan unioni - islanti - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.